 BRISBANE, Calif., May 12, 2022 GLOBE NEWSWIRE -- GT Biopharma, Inc. NASDAQ: GTBP, an immuno-oncology company focused on developing innovative therapeutics based on the Companys proprietary tri-specific natural killer NK cell engager, TriKE protein biologic technology platform, announced that management will present at H.C. Wainwrights Hybrid Global Investment Conference. The conference will take place May 23-26, 2022 at the Fontainebleau, Miami Beach Hotel, Miami Beach, Florida. 